Status of protein engineering for biocatalysts: how to design an industrially useful biocatalyst.
Recent advances in the development of both experimental and computational protein engineering tools have enabled a number of further successes in the development of biocatalysts ready for large-scale applications. Key tools are first, the targeting of libraries, leading to far smaller but more useful libraries than in the past, second, the combination of structural, mechanistic, and sequence-based knowledge often based on prior successful cases, and third, the advent of structurally based algorithms allowing the design of novel functions. Based on these tools, a number of improved biocatalysts for pharmaceutical applications have been presented, such as an (R)-transaminase for the synthesis of active pharmaceutical ingredients (APIs) of sitagliptin (Januvia®) and ketoreductases, glucose dehydrogenases, and haloalkane dehalogenases for the API synthesis toward atorvastatin (Lipitor®) and montelukast (Singulair®).
School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, 315 Ferst Drive, Atlanta, GA 30332-0363, USA. andreas.bommarius@chbe.gatech.edu
Andreas S
AS
Bommarius
Janna K
JK
Blum
Michael J
MJ
Abrahamson
D000818:Animals; D055162:Biocatalysis; D019295:Computational Biology / Q000379:methods / Q000639:trends*; D006801:Humans; D008958:Models, Molecular; D015202:Protein Engineering / Q000379:methods / Q000639:trends*; D011506:Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism
D011506:Proteins